GSK plc

GSK plc Financial Leverage

The Financial Leverage (Equity Multiplier) of GSK plc (GSK.L) as of Nov 9, 2026 is 3.73. In the previous year, Financial Leverage (Equity Multiplier) was 4.35 — a change of -14.20% (lower).

Financial Leverage

3.73

YoY

-14.20%

Last updated:

Financial Leverage (Equity Multiplier) of GSK plc is 2025 3.73 . Financial Leverage (Equity Multiplier) of GSK plc was 2024 4.35 . It decreases by -14.20% lower compared to the previous year.

The GSK plc Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
15.36 GBP
Jan 1, 2019
6.99 GBP
Jan 1, 2020
5.51 GBP
Jan 1, 2021
5.25 GBP
Jan 1, 2022
5.68 GBP
Jan 1, 2023
4.42 GBP
Jan 1, 2024
4.35 GBP
Jan 1, 2025
3.73 GBP
The GSK plc Financial Leverage history
YEARFinancial LeverageYoY
3.73-14.20%
4.35-1.61%
4.42-22.10%
5.68+8.01%
5.25-4.71%
5.51-21.09%
6.99-54.50%
15.36-101.85%
-829.13-1,677.40%
52.56+402.95%
10.45+9.60%
9.54—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Financial Leverage (Equity Multiplier) of GSK plc is 3.73 in 2025.

Financial Leverage (Equity Multiplier) of GSK plc changed from 4.35 to 3.73, representing a -14.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) GSK plc since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s GSK plc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GSK plc

All Key Metrics — GSK plc